PDS Biotechnology announced the issuance of a new patent for PDS0101 in Japan, expanding its composition claims.
The patent further strengthens the company's intellectual property portfolio globally, securing market protections for PDS0101 until the 2040s.
PDS0101 is a key focus in the company's Phase 3 trial for HPV16-positive recurrent/metastatic head and neck cancer.
New Patent Grant in Japan
Japan Patent Office issued Patent No. 7783866 for PDS0101 with broad composition claims.
Robust IP Portfolio
Company's intellectual property estate includes patents in the US, China, Australia, and Hong Kong.
- The new patent strengthens PDS Biotech's global IP portfolio.
- Market exclusivity for PDS0101 secured till the 2040s enhances long-term revenue potential.
PDS Biotech's latest patent grant in Japan enhances its global IP portfolio, solidifying its position in the immunotherapy sector. With market exclusivity for PDS0101 extended till the 2040s, the company is poised for continued growth.